Importer of Controlled Substances Application: Lipomed, 15627-15630 [2018-07442]

Download as PDF Federal Register / Vol. 83, No. 70 / Wednesday, April 11, 2018 / Notices Issued: April 5, 2018. Lisa Barton, Secretary to the Commission. [FR Doc. 2018–07412 Filed 4–10–18; 8:45 am] BILLING CODE 7020–02–P INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–1102] Certain Light Engines and Components Thereof; Commission Determination Not To Review an Initial Determination Granting a Joint Motion To Terminate the Investigation in Its Entirety Based Upon a Consent Order Stipulation; Issuance of Consent Order U.S. International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that the U.S. International Trade Commission has determined not to review the presiding administrative law judge’s (‘‘ALJ’’) initial determination (‘‘ID’’) (Order No. 2) granting a joint motion to terminate the investigation in its entirety based upon a consent order stipulation; entry of consent order and termination of investigation. FOR FURTHER INFORMATION CONTACT: Panyin A. Hughes, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone 202– 205–3042. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (https://www.usitc.gov). The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at https:// edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on 202–205–1810. SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on March 16, 2018, based on a complaint filed by Lumencor, Inc. of Beaverton, Oregon (‘‘Lumencor’’). 83 FR 11789 (Mar. 16, 2018). The complaint alleges violations of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), in the importation into the United States, the sale for importation, amozie on DSK30RV082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:17 Apr 10, 2018 Jkt 244001 and the sale within the United States after importation of certain light engines and components thereof by reason of infringement of one or more of claims 1–6, 10, 11, and 16–19 of U.S. Patent No. 9,574,722 (‘‘the ’722 patent’’); claims 1–3, 5, 7, 9, 11–13, 15, 17, and 20 of U.S. Patent No. 9,395,055 (‘‘the ’055 patent’’); and claims 1, 4, 6, 7, 9, 16, and 18 of U.S. Patent No. 8,493,564 (‘‘the ’564 patent’’). The notice of investigation named the following respondents: Excelitas Technologies Corp. of Waltham, Massachusetts and Lumen Dynamics Group, Inc. of Mississauga, Ontario, Canada (collectively, ‘‘Respondents’’). The Office of Unfair Import Investigations is not a party to the investigation. On March 15, 2018, Lumencor and Respondents filed a joint motion to terminate the investigation in its entirety based upon consent order stipulation. No responses to the motion were filed. We note that the Commission issued its notice to institute this investigation on March 12, 2018, but the notice did not appear in the Federal Register until March 16, 2018. On March 20, 2018, the ALJ issued the subject ID, granting the motion. On March 26, 2018, the ALJ issued errata correcting a typographical error on page 2 of the ID (changing ‘‘Lumencor also agrees to’’ to ‘‘Respondents also agree to’’). The ALJ found that the consent order stipulation complies with the requirements of Commission Rule 210.21(c)(3) (19 CFR 210.21(c)(3)), and that terminating the investigation in its entirety would not be contrary to the public interest. None of the parties petitioned for review of the ID. The Commission has determined not to review the ID and to issue consent order herewith. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: April 6, 2018. Lisa Barton, Secretary to the Commission. BILLING CODE 7020–02–P PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—ASTM International Standards Notice is hereby given that, on February 21, 2018, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), ASTM International (‘‘ASTM’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing additions or changes to its standards development activities. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, ASTM has provided an updated list of current, ongoing ASTM standards activities originating between December 2017 and February 2018 designated as work items. A complete listing of ASTM Work Items along with a brief description of each, is available at https://www.astm.org. On September 15, 2004, ASTM filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on November 10, 2004 (69 FR 65226). The last notification with the Department was filed on December 14, 2017. A notice was filed in the Federal Register on February 12, 2018 (83 FR 6050). Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. [FR Doc. 2018–07514 Filed 4–10–18; 8:45 am] BILLING CODE 4410–11–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Lipomed ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before May 11, 2018. Such persons may also file a written request for a DATES: [FR Doc. 2018–07452 Filed 4–10–18; 8:45 am] 15627 E:\FR\FM\11APN1.SGM 11APN1 15628 Federal Register / Vol. 83, No. 70 / Wednesday, April 11, 2018 / Notices hearing on the application on or before May 11, 2018. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on January 22, 2016, Lipomed, 150 Cambridge Park Drive, Suite 705, Cambridge, MA 02140 applied to be registered as an importer of the following basic classes of controlled substances: amozie on DSK30RV082PROD with NOTICES Controlled substance Drug code Cathinone ................................................................................................................................................................ Methcathinone ......................................................................................................................................................... Mephedrone (4-Methyl-N-methylcathinone) ............................................................................................................ N-Ethylamphetamine ............................................................................................................................................... N,N-Dimethylamphetamine ...................................................................................................................................... Fenethylline ............................................................................................................................................................. Aminorex ................................................................................................................................................................. 4-Methylaminorex (cis isomer) ................................................................................................................................ Gamma Hydroxybutyric Acid ................................................................................................................................... Methaqualone .......................................................................................................................................................... Mecloqualone .......................................................................................................................................................... JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) .......................................................................................... SR–18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ........................................ JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) .............................................................................................................. JWH–081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) .......................................................................................... SR–19 (Also known as RCS–4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole ............................................................ JWH–018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) ...................................................................... JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) ............................................................................................. JWH–073 (1-Butyl-3-(1-naphthoyl)indole) ............................................................................................................... JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) .................................................................................. AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) ............................................................................................... JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) .............................................................................................. Alpha-ethyltryptamine .............................................................................................................................................. Ibogaine ................................................................................................................................................................... CP–47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) ........................................................ CP–47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol) .................................. Lysergic acid diethylamide ...................................................................................................................................... 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C–T–7) ...................................................................................... Marihuana ................................................................................................................................................................ Tetrahydrocannabinols ............................................................................................................................................ Parahexyl ................................................................................................................................................................. Mescaline ................................................................................................................................................................ 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C–T–2 ) .................................................................................. 3,4,5-Trimethoxyamphetamine ................................................................................................................................ 4-Bromo-2,5-dimethoxyamphetamine ..................................................................................................................... 4-Bromo-2,5-dimethoxyphenethylamine .................................................................................................................. 4-Methyl-2,5-dimethoxyamphetamine ..................................................................................................................... 2,5-Dimethoxyamphetamine .................................................................................................................................... JWH–398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole) .............................................................................................. 2,5-Dimethoxy-4-ethylamphetamine ........................................................................................................................ 3,4-Methylenedioxyamphetamine ............................................................................................................................ 5-Methoxy-3,4-methylenedioxyamphetamine .......................................................................................................... N-Hydroxy-3,4-methylenedioxyamphetamine .......................................................................................................... 3,4-Methylenedioxy-N-ethylamphetamine ............................................................................................................... 3,4-Methylenedioxymethamphetamine .................................................................................................................... 4-Methoxyamphetamine .......................................................................................................................................... 5-Methoxy-N–N-dimethyltryptamine ........................................................................................................................ Alpha-methyltryptamine ........................................................................................................................................... Bufotenine ............................................................................................................................................................... Psilocybin ................................................................................................................................................................ Psilocyn ................................................................................................................................................................... 5-Methoxy-N,N-diisopropyltryptamine ..................................................................................................................... N-Ethyl-1-phenylcyclohexylamine ............................................................................................................................ 1-[1-(2-Thienyl)cyclohexyl]piperidine ....................................................................................................................... 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine ...................................................................................................................... VerDate Sep<11>2014 17:17 Apr 10, 2018 Jkt 244001 PO 00000 Frm 00079 Fmt 4703 Sfmt 4703 E:\FR\FM\11APN1.SGM 11APN1 1235 1237 1248 1475 1480 1503 1585 1590 2010 2565 2572 6250 7008 7019 7081 7104 7118 7122 7173 7200 7201 7203 7249 7260 7297 7298 7315 7348 7360 7370 7374 7381 7385 7390 7391 7392 7395 7396 7398 7399 7400 7401 7402 7404 7405 7411 7431 7432 7433 7437 7438 7439 7455 7470 7473 Schedule I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. 15629 Federal Register / Vol. 83, No. 70 / Wednesday, April 11, 2018 / Notices amozie on DSK30RV082PROD with NOTICES Controlled substance Drug code N-Ethyl-3-piperidyl benzilate .................................................................................................................................... N-Methyl-3-piperidyl benzilate ................................................................................................................................. N-Benzylpiperazine ................................................................................................................................................. 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C–D) .......................................................................................... 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C–E ) ............................................................................................ 2-(2,5-Dimethoxyphenyl) ethanamine (2C–H) ......................................................................................................... 2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2C–I) ................................................................................................ 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C–C) .......................................................................................... 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C–N) ............................................................................................ 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C–P) ..................................................................................... 2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine (2C–T–4) ............................................................................ MDPV (3,4-Methylenedioxypyrovalerone) ............................................................................................................... Methylone (3,4-Methylenedioxy-N-methylcathinone) .............................................................................................. AM–694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole) ........................................................................................... Acetyldihydrocodeine .............................................................................................................................................. Benzylmorphine ....................................................................................................................................................... Codeine-N-oxide ...................................................................................................................................................... Cyprenorphine ......................................................................................................................................................... Desomorphine ......................................................................................................................................................... Etorphine (except HCl) ............................................................................................................................................ Codeine methylbromide ........................................................................................................................................... Dihydromorphine ..................................................................................................................................................... Difenoxin .................................................................................................................................................................. Heroin ...................................................................................................................................................................... Hydromorphinol ....................................................................................................................................................... Methyldesorphine .................................................................................................................................................... Methyldihydromorphine ........................................................................................................................................... Morphine methylbromide ......................................................................................................................................... Morphine methylsulfonate ....................................................................................................................................... Morphine-N-oxide .................................................................................................................................................... Myrophine ................................................................................................................................................................ Nicocodeine ............................................................................................................................................................. Nicomorphine .......................................................................................................................................................... Normorphine ............................................................................................................................................................ Pholcodine ............................................................................................................................................................... Thebacon ................................................................................................................................................................. Acetorphine ............................................................................................................................................................. Acetylmethadol ........................................................................................................................................................ Allylprodine .............................................................................................................................................................. Alphacetylmethadol except levo-alphacetylmethadol .............................................................................................. Alphamethadol ......................................................................................................................................................... Dioxaphetyl butyrate ................................................................................................................................................ Dipipanone .............................................................................................................................................................. Ethylmethylthiambutene .......................................................................................................................................... Etonitazene .............................................................................................................................................................. Etoxeridine ............................................................................................................................................................... Furethidine ............................................................................................................................................................... Hydroxypethidine ..................................................................................................................................................... Ketobemidone ......................................................................................................................................................... Levomoramide ......................................................................................................................................................... Levophenacylmorphan ............................................................................................................................................ Morpheridine ............................................................................................................................................................ Noracymethadol ...................................................................................................................................................... Norlevorphanol ........................................................................................................................................................ Normethadone ......................................................................................................................................................... Norpipanone ............................................................................................................................................................ Phenadoxone .......................................................................................................................................................... Phenampromide ...................................................................................................................................................... Phenoperidine ......................................................................................................................................................... Piritramide ............................................................................................................................................................... Proheptazine ........................................................................................................................................................... Properidine .............................................................................................................................................................. Racemoramide ........................................................................................................................................................ Trimeperidine ........................................................................................................................................................... Phenomorphan ........................................................................................................................................................ Propiram .................................................................................................................................................................. Tilidine ..................................................................................................................................................................... Para-Fluorofentanyl ................................................................................................................................................. 3-Methylfentanyl ...................................................................................................................................................... Acetyl-alpha-methylfentanyl ..................................................................................................................................... Beta-hydroxy-3-methylfentanyl ................................................................................................................................ Amphetamine .......................................................................................................................................................... Methamphetamine ................................................................................................................................................... Lisdexamfetamine ................................................................................................................................................... VerDate Sep<11>2014 17:17 Apr 10, 2018 Jkt 244001 PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 E:\FR\FM\11APN1.SGM 11APN1 7482 7484 7493 7508 7509 7517 7518 7519 7521 7524 7532 7535 7540 7694 9051 9052 9053 9054 9055 9056 9070 9145 9168 9200 9301 9302 9304 9305 9306 9307 9308 9309 9312 9313 9314 9315 9319 9601 9602 9603 9605 9621 9622 9623 9624 9625 9626 9627 9628 9629 9631 9632 9633 9634 9635 9636 9637 9638 9641 9642 9643 9644 9645 9646 9647 9649 9750 9812 9813 9815 9831 1100 1105 1205 Schedule I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. I. II. II. II. 15630 Federal Register / Vol. 83, No. 70 / Wednesday, April 11, 2018 / Notices Controlled substance Drug code amozie on DSK30RV082PROD with NOTICES Phenmetrazine ........................................................................................................................................................ Methylphenidate ...................................................................................................................................................... Amobarbital ............................................................................................................................................................. Pentobarbital ........................................................................................................................................................... Secobarbital ............................................................................................................................................................. Glutethimide ............................................................................................................................................................ Nabilone .................................................................................................................................................................. 1-Phenylcyclohexylamine ........................................................................................................................................ Phencyclidine .......................................................................................................................................................... 4-Anilino-N-phenethyl-4-piperidine (ANPP) ............................................................................................................. Phenylacetone ......................................................................................................................................................... 1-Piperidinocyclohexanecarbonitrile ........................................................................................................................ Alphaprodine ........................................................................................................................................................... Anileridine ................................................................................................................................................................ Cocaine ................................................................................................................................................................... Codeine ................................................................................................................................................................... Etorphine HCl .......................................................................................................................................................... Dihydrocodeine ........................................................................................................................................................ Oxycodone .............................................................................................................................................................. Hydromorphone ....................................................................................................................................................... Diphenoxylate .......................................................................................................................................................... Ecgonine .................................................................................................................................................................. Ethylmorphine .......................................................................................................................................................... Hydrocodone ........................................................................................................................................................... Levomethorphan ...................................................................................................................................................... Levorphanol ............................................................................................................................................................. Isomethadone .......................................................................................................................................................... Meperidine ............................................................................................................................................................... Meperidine intermediate-B ...................................................................................................................................... Metazocine .............................................................................................................................................................. Methadone ............................................................................................................................................................... Methadone intermediate .......................................................................................................................................... Metopon ................................................................................................................................................................... Dextropropoxyphene, bulk (non-dosage forms) ...................................................................................................... Morphine .................................................................................................................................................................. Thebaine .................................................................................................................................................................. Dihydroetorphine ..................................................................................................................................................... Levo-alphacetylmethadol ......................................................................................................................................... Oxymorphone .......................................................................................................................................................... Noroxymorphone ..................................................................................................................................................... Phenazocine ............................................................................................................................................................ Piminodine ............................................................................................................................................................... Racemethorphan ..................................................................................................................................................... Racemorphan .......................................................................................................................................................... Alfentanil .................................................................................................................................................................. Remifentanil ............................................................................................................................................................. Sufentanil ................................................................................................................................................................. Carfentanil ............................................................................................................................................................... Tapentadol ............................................................................................................................................................... Bezitramide .............................................................................................................................................................. Fentanyl ................................................................................................................................................................... The company plans to import analytical reference standards for distribution to its customers for research and analytical purposes. Placement of these drug codes onto the company’s registration does not translate into automatic approval of subsequent permit applications to import controlled substances. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale. VerDate Sep<11>2014 17:17 Apr 10, 2018 Jkt 244001 Dated: April 4, 2018. Susan A. Gibson, Deputy Assistant Administrator. [FR Doc. 2018–07442 Filed 4–10–18; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. 17–46] Witold Marek Zajewski, M.D.; Decision and Order On July 27, 2017, the Acting Assistant Administrator, Diversion Control Division, Drug Enforcement PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 1631 1724 2125 2270 2315 2550 7379 7460 7471 8333 8501 8603 9010 9020 9041 9050 9059 9120 9143 9150 9170 9180 9190 9193 9210 9220 9226 9230 9233 9240 9250 9254 9260 9273 9300 9333 9334 9648 9652 9668 9715 9730 9732 9733 9737 9739 9740 9743 9780 9800 9801 Schedule II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. II. Administration (DEA), issued an Order to Show Cause to Witold Marek Zajewski, M.D. (Respondent), of Mount Prospect, Illinois. The Show Cause Order proposed the revocation of Respondent’s DEA Certificate of Registration No. BZ5641419 on the ground that he has ‘‘no state authority to handle controlled substances.’’ Order to Show Cause, at 1 (citing 21 U.S.C. 824(a)(3)). For the same reason, the Order also proposed the denial of any of Respondent’s ‘‘applications for renewal or modification of such registration and any applications for any other DEA registrations. Id. With respect to the Agency’s jurisdiction, the Show Cause Order E:\FR\FM\11APN1.SGM 11APN1

Agencies

[Federal Register Volume 83, Number 70 (Wednesday, April 11, 2018)]
[Notices]
[Pages 15627-15630]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-07442]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: Lipomed

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before May 11, 2018. Such 
persons may also file a written request for a

[[Page 15628]]

hearing on the application on or before May 11, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
request for hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.34(a), this is notice that on 
January 22, 2016, Lipomed, 150 Cambridge Park Drive, Suite 705, 
Cambridge, MA 02140 applied to be registered as an importer of the 
following basic classes of controlled substances:

------------------------------------------------------------------------
      Controlled substance           Drug code           Schedule
------------------------------------------------------------------------
Cathinone.......................            1235  I.
Methcathinone...................            1237  I.
Mephedrone (4-Methyl-N-                     1248  I.
 methylcathinone).
N-Ethylamphetamine..............            1475  I.
N,N-Dimethylamphetamine.........            1480  I.
Fenethylline....................            1503  I.
Aminorex........................            1585  I.
4-Methylaminorex (cis isomer)...            1590  I.
Gamma Hydroxybutyric Acid.......            2010  I.
Methaqualone....................            2565  I.
Mecloqualone....................            2572  I.
JWH-250 (1-Pentyl-3-(2-                     6250  I.
 methoxyphenylacetyl) indole).
SR-18 (Also known as RCS-8) (1-             7008  I.
 Cyclohexylethyl-3-(2-
 methoxyphenylacetyl) indole).
JWH-019 (1-Hexyl-3-(1-                      7019  I.
 naphthoyl)indole).
JWH-081 (1-Pentyl-3-(1-(4-                  7081  I.
 methoxynaphthoyl) indole).
SR-19 (Also known as RCS-4) (1-             7104  I.
 Pentyl-3-[(4-methoxy)-benzoyl]
 indole.
JWH-018 (also known as AM678) (1-           7118  I.
 Pentyl-3-(1-naphthoyl)indole).
JWH-122 (1-Pentyl-3-(4-methyl-1-            7122  I.
 naphthoyl) indole).
JWH-073 (1-Butyl-3-(1-                      7173  I.
 naphthoyl)indole).
JWH-200 (1-[2-(4-                           7200  I.
 Morpholinyl)ethyl]-3-(1-
 naphthoyl)indole).
AM2201 (1-(5-Fluoropentyl)-3-(1-            7201  I.
 naphthoyl) indole).
JWH-203 (1-Pentyl-3-(2-                     7203  I.
 chlorophenylacetyl) indole).
Alpha-ethyltryptamine...........            7249  I.
Ibogaine........................            7260  I.
CP-47,497 (5-(1,1-                          7297  I.
 Dimethylheptyl)-2-[(1R,3S)-3-
 hydroxycyclohexyl-phenol).
CP-47,497 C8 Homologue (5-(1,1-             7298  I.
 Dimethyloctyl)-2-[(1R,3S)3-
 hydroxycyclohexyl-phenol).
Lysergic acid diethylamide......            7315  I.
2,5-Dimethoxy-4-(n)-                        7348  I.
 propylthiophenethylamine (2C-T-
 7).
Marihuana.......................            7360  I.
Tetrahydrocannabinols...........            7370  I.
Parahexyl.......................            7374  I.
Mescaline.......................            7381  I.
2-(4-Ethylthio-2,5-                         7385  I.
 dimethoxyphenyl) ethanamine (2C-
 T-2 ).
3,4,5-Trimethoxyamphetamine.....            7390  I.
4-Bromo-2,5-dimethoxyamphetamine            7391  I.
4-Bromo-2,5-                                7392  I.
 dimethoxyphenethylamine.
4-Methyl-2,5-                               7395  I.
 dimethoxyamphetamine.
2,5-Dimethoxyamphetamine........            7396  I.
JWH-398 (1-Pentyl-3-(4-chloro-1-            7398  I.
 naphthoyl) indole).
2,5-Dimethoxy-4-ethylamphetamine            7399  I.
3,4-Methylenedioxyamphetamine...            7400  I.
5-Methoxy-3,4-                              7401  I.
 methylenedioxyamphetamine.
N-Hydroxy-3,4-                              7402  I.
 methylenedioxyamphetamine.
3,4-Methylenedioxy-N-                       7404  I.
 ethylamphetamine.
3,4-                                        7405  I.
 Methylenedioxymethamphetamine.
4-Methoxyamphetamine............            7411  I.
5-Methoxy-N-N-dimethyltryptamine            7431  I.
Alpha-methyltryptamine..........            7432  I.
Bufotenine......................            7433  I.
Psilocybin......................            7437  I.
Psilocyn........................            7438  I.
5-Methoxy-N,N-                              7439  I.
 diisopropyltryptamine.
N-Ethyl-1-phenylcyclohexylamine.            7455  I.
1-[1-(2-                                    7470  I.
 Thienyl)cyclohexyl]piperidine.
1-[1-(2-                                    7473  I.
 Thienyl)cyclohexyl]pyrrolidine.

[[Page 15629]]

 
N-Ethyl-3-piperidyl benzilate...            7482  I.
N-Methyl-3-piperidyl benzilate..            7484  I.
N-Benzylpiperazine..............            7493  I.
2-(2,5-Dimethoxy-4-methylphenyl)            7508  I.
 ethanamine (2C-D).
2-(2,5-Dimethoxy-4-ethylphenyl)             7509  I.
 ethanamine (2C-E ).
2-(2,5-Dimethoxyphenyl)                     7517  I.
 ethanamine (2C-H).
2-(4-iodo-2,5-dimethoxyphenyl)              7518  I.
 ethanamine (2C-I).
2-(4-Chloro-2,5-dimethoxyphenyl)            7519  I.
 ethanamine (2C-C).
2-(2,5-Dimethoxy-4-nitro-phenyl)            7521  I.
 ethanamine (2C-N).
2-(2,5-Dimethoxy-4-(n)-                     7524  I.
 propylphenyl) ethanamine (2C-P).
2-(4-Isopropylthio)-2,5-                    7532  I.
 dimethoxyphenyl) ethanamine (2C-
 T-4).
MDPV (3,4-                                  7535  I.
 Methylenedioxypyrovalerone).
Methylone (3,4-Methylenedioxy-N-            7540  I.
 methylcathinone).
AM-694 (1-(5-Fluoropentyl)-3-(2-            7694  I.
 iodobenzoyl) indole).
Acetyldihydrocodeine............            9051  I.
Benzylmorphine..................            9052  I.
Codeine-N-oxide.................            9053  I.
Cyprenorphine...................            9054  I.
Desomorphine....................            9055  I.
Etorphine (except HCl)..........            9056  I.
Codeine methylbromide...........            9070  I.
Dihydromorphine.................            9145  I.
Difenoxin.......................            9168  I.
Heroin..........................            9200  I.
Hydromorphinol..................            9301  I.
Methyldesorphine................            9302  I.
Methyldihydromorphine...........            9304  I.
Morphine methylbromide..........            9305  I.
Morphine methylsulfonate........            9306  I.
Morphine-N-oxide................            9307  I.
Myrophine.......................            9308  I.
Nicocodeine.....................            9309  I.
Nicomorphine....................            9312  I.
Normorphine.....................            9313  I.
Pholcodine......................            9314  I.
Thebacon........................            9315  I.
Acetorphine.....................            9319  I.
Acetylmethadol..................            9601  I.
Allylprodine....................            9602  I.
Alphacetylmethadol except levo-             9603  I.
 alphacetylmethadol.
Alphamethadol...................            9605  I.
Dioxaphetyl butyrate............            9621  I.
Dipipanone......................            9622  I.
Ethylmethylthiambutene..........            9623  I.
Etonitazene.....................            9624  I.
Etoxeridine.....................            9625  I.
Furethidine.....................            9626  I.
Hydroxypethidine................            9627  I.
Ketobemidone....................            9628  I.
Levomoramide....................            9629  I.
Levophenacylmorphan.............            9631  I.
Morpheridine....................            9632  I.
Noracymethadol..................            9633  I.
Norlevorphanol..................            9634  I.
Normethadone....................            9635  I.
Norpipanone.....................            9636  I.
Phenadoxone.....................            9637  I.
Phenampromide...................            9638  I.
Phenoperidine...................            9641  I.
Piritramide.....................            9642  I.
Proheptazine....................            9643  I.
Properidine.....................            9644  I.
Racemoramide....................            9645  I.
Trimeperidine...................            9646  I.
Phenomorphan....................            9647  I.
Propiram........................            9649  I.
Tilidine........................            9750  I.
Para-Fluorofentanyl.............            9812  I.
3-Methylfentanyl................            9813  I.
Acetyl-alpha-methylfentanyl.....            9815  I.
Beta-hydroxy-3-methylfentanyl...            9831  I.
Amphetamine.....................            1100  II.
Methamphetamine.................            1105  II.
Lisdexamfetamine................            1205  II.

[[Page 15630]]

 
Phenmetrazine...................            1631  II.
Methylphenidate.................            1724  II.
Amobarbital.....................            2125  II.
Pentobarbital...................            2270  II.
Secobarbital....................            2315  II.
Glutethimide....................            2550  II.
Nabilone........................            7379  II.
1-Phenylcyclohexylamine.........            7460  II.
Phencyclidine...................            7471  II.
4-Anilino-N-phenethyl-4-                    8333  II.
 piperidine (ANPP).
Phenylacetone...................            8501  II.
1-                                          8603  II.
 Piperidinocyclohexanecarbonitri
 le.
Alphaprodine....................            9010  II.
Anileridine.....................            9020  II.
Cocaine.........................            9041  II.
Codeine.........................            9050  II.
Etorphine HCl...................            9059  II.
Dihydrocodeine..................            9120  II.
Oxycodone.......................            9143  II.
Hydromorphone...................            9150  II.
Diphenoxylate...................            9170  II.
Ecgonine........................            9180  II.
Ethylmorphine...................            9190  II.
Hydrocodone.....................            9193  II.
Levomethorphan..................            9210  II.
Levorphanol.....................            9220  II.
Isomethadone....................            9226  II.
Meperidine......................            9230  II.
Meperidine intermediate-B.......            9233  II.
Metazocine......................            9240  II.
Methadone.......................            9250  II.
Methadone intermediate..........            9254  II.
Metopon.........................            9260  II.
Dextropropoxyphene, bulk (non-              9273  II.
 dosage forms).
Morphine........................            9300  II.
Thebaine........................            9333  II.
Dihydroetorphine................            9334  II.
Levo-alphacetylmethadol.........            9648  II.
Oxymorphone.....................            9652  II.
Noroxymorphone..................            9668  II.
Phenazocine.....................            9715  II.
Piminodine......................            9730  II.
Racemethorphan..................            9732  II.
Racemorphan.....................            9733  II.
Alfentanil......................            9737  II.
Remifentanil....................            9739  II.
Sufentanil......................            9740  II.
Carfentanil.....................            9743  II.
Tapentadol......................            9780  II.
Bezitramide.....................            9800  II.
Fentanyl........................            9801  II.
------------------------------------------------------------------------

    The company plans to import analytical reference standards for 
distribution to its customers for research and analytical purposes. 
Placement of these drug codes onto the company's registration does not 
translate into automatic approval of subsequent permit applications to 
import controlled substances. Approval of permit applications will 
occur only when the registrant's business activity is consistent with 
what is authorized under 21 U.S.C. 952(a)(2). Authorization will not 
extend to the import of FDA approved or non-approved finished dosage 
forms for commercial sale.

    Dated: April 4, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
[FR Doc. 2018-07442 Filed 4-10-18; 8:45 am]
 BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.